Prescription Questionnaires on HMG-CoA Reductase Inhibitors for General Practitioners
10.11256/jjdi.11.223
- VernacularTitle:スタチン系薬剤の使用に関する臨床医に対する意識調査
- Author:
Kaori Kadoyama
;
Akiko Kuwahara
;
Yoshio Fujioka
;
Nobutaka Inoue
;
Mitsukazu Yamane
;
Toshiyuki Sakaeda
;
Yuichi Ishikawa
- Publication Type:Journal Article
- Keywords:
hyperlipidemia;
questionnaire;
HMG-CoA redactase inhibitor (statin);
guideline;
adverse events
- From:Japanese Journal of Drug Informatics
2010;11(4):223-231
- CountryJapan
- Language:Japanese
-
Abstract:
Objective: To clarify the reason why the target levels of low-density lipoprotein (LDL)-cholesterol are hardly attained.
Methods: The questionnaire was performed for 237 general practitioners on prescription of HMG-CoA reductase inhibitors (statins), just after the publication of “Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007”.
Results: The responses could be summarized as 1) almost all doctors recognized the significance of target levels of LDL-cholesterol; 2) however, general physicians have such a recognition to a lesser extent, compared with cardiologists; 3) when prescribing statins, 66.2% of them had concerns about drug-drug interactions; 4) as the adverse events with statins, they listed creatine kinase (CK) elevations (86.5%), hepatic dysfunction (74.3%) and myalgias/rhabdomyolysis (70.9%); 5) in contrast, less than 20% of them listed the fulminant hepatic failure, gastrointestinal symptoms and fluctuation of blood glucose levels; 6) the threshold value of CK to discontinue statins was 500 IU/L in 44.4% and 200-300 IU/L in 39.6%; and 7) 78.5% of them believed that statins have the pleiotropic ability such a anti-inflammatory effect clinically, in addition to lipid-lowering.
Conclusions: It is important to serve the drug information about the safety of statins to the general practitioners for the management of hyperlipidemia, based on original articles.
